Stockpolly
Search
Delisting risk
PTPI · NASDAQ · Drug Manufacturers - Specialty & Generic

Petros Pharmaceuticals (PTPI)

Builds SaaS and SaMD tools for prescription-to-OTC drug switches.

$0.0047
At close−0.00 (−6.00%)
Watchlist

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Revenue201121000000
Cost of revenue001000000000
Gross profit1−10110000000
6543410121011
Research & development012010000000
Selling, general & administrative233221120011
Other expenses410118001000
Operating income−5−5−4−2−2−9−1−2−10−1−1
052200000000
Interest income000000000000
Interest expense000000000000
Other non-operating income0−5−2−200000000
Income before tax−50−2−1−2−9−1−2−10−1−1
Net income from continuing operations−50−2−1−2−9−1−2−10−1−1
Discontinued operations000000−110700
Other adjustments000000070−700
Net income−50−2−1−2−9−25−10−1−1
EPS, basic−$2.85−$2.10−$1.69−$0.37−$1.15−$0.13−$9.37−$1.29−$0.03$8.58−$0.02−$0.02
EPS, diluted−$2.85−$2.10−$1.69−$0.37−$0.53−$0.13−$9.37−$1.29−$0.03$8.58−$0.02−$0.02
Weighted average shares, basic221248126422814647
Weighted average shares, diluted2257108126422814647
EBITDA−41−10−1−8−1−200−1−1
Depreciation & amortization111111001000
EBIT−40−2−1−2−9−1−2−10−10